And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines
The Dermatology Digest
MARCH 5, 2024
Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Hugel filed its first Biologics License Application in 2021, which was rejected by the FDA in 2022. Now, there are six neuromodulators approved for cosmetic use in the U.S.:
Let's personalize your content